Parámetros cuantitativos de la PET/TC con
Aged
Aged, 80 and over
Area Under Curve
Carcinoma, Non-Small-Cell Lung
/ diagnostic imaging
Combined Modality Therapy
Cone-Beam Computed Tomography
Female
Fluorine Radioisotopes
Fluorodeoxyglucose F18
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Lung Neoplasms
/ diagnostic imaging
Male
Middle Aged
Neoplasm Recurrence, Local
Positron Emission Tomography Computed Tomography
/ methods
Prognosis
Proportional Hazards Models
Prospective Studies
ROC Curve
Radiopharmaceuticals
Radiosurgery
Radiotherapy, Intensity-Modulated
Cáncer de pulmón
Lung cancer
MTV
PET/CT
PET/TC
SBRT
SUV
TLG
Journal
Revista espanola de medicina nuclear e imagen molecular
ISSN: 2253-8089
Titre abrégé: Rev Esp Med Nucl Imagen Mol (Engl Ed)
Pays: Spain
ID NLM: 101770941
Informations de publication
Date de publication:
Historique:
received:
25
04
2020
revised:
23
05
2020
accepted:
25
05
2020
pubmed:
2
7
2020
medline:
8
10
2021
entrez:
2
7
2020
Statut:
ppublish
Résumé
To assess the utility of Fifty patients (42 men) diagnosed in the last 7years with early-stage lung cancer and treated with SBRT alone were assessed by a prospective study. After PET/CT study, metabolic parameters maximum SUV (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were determined at different thresholds. The prognostic factors for overall survival (OS), cause-specific survival (CS) and disease-free survival (DFS) were analysed by Cox proportional hazards model and the survival analysis by Kaplan-Meier method. The average follow-up was 39.6months, with 21 recurrences and 24 dead. Univariate analysis determined MTV Pre-treatment quantitative assessment using metabolic parameters MTV
Identifiants
pubmed: 32605894
pii: S2253-654X(20)30083-4
doi: 10.1016/j.remn.2020.05.008
pii:
doi:
Substances chimiques
Fluorine Radioisotopes
0
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Fluorine-18
GZ5I74KB8G
Types de publication
Journal Article
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
353-359Informations de copyright
Copyright © 2020 Sociedad Española de Medicina Nuclear e Imagen Molecular. Publicado por Elsevier España, S.L.U. All rights reserved.